Curevac N.V. (CVAC) Stock Price, Quote & News

Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company's portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRNAs to stimulate the production of therapeutic proteins utilizing its technology and instructs human cells to produce or secrete specific proteins in the nucleus, cytopl...

Industry: Biotechnology

Sector: Healthcare

Phone: 49 7071 9883 0

Website: www.curevac.com

Address:

Friedrich-Miescher-Strasse 15, Tübingen, Germany

Jordand91 Jul. 11 at 6:55 PM

$NVAX go and check out $CVAC has a lot more promise than nova. Actually everything at this point has more promise than nova

2 · Reply

taxplanr Jul. 11 at 1:10 PM

$BNTX $MRNA $CVAC $BMY there is no future for malignantRNA in medicine

1 · Reply

taxplanr Jul. 9 at 2:20 PM

$BNTX $MRNA $CVAC $NVAX only sales plan https://jonfleetwood.substack.com/p/pegasus-uk-to-run-largest-ever-national

0 · Reply

StocktwitsNews Jul. 8 at 5:05 AM

Cooling US Bird Flu Wave Removes Tailwind For Moderna, Novavax, CureVac, Traws Pharma $MRNA $NVAX $CVAC $GSK $TRAW https://stocktwits.com/news/equity/markets/cooling-us-bird-flu-wave-removes-tailwind-for-moderna-novavax-cure-vac-traws-pharma/chFvLokR5Qy

1 · Reply

justiceforb_85 Jul. 3 at 8:05 PM

$CVAC when does the deal close?

0 · Reply

taxplanr Jun. 30 at 2:31 PM

$MRNA $BNTX $CVAC $BMY please let everyone know about the Ivermectin Menbendazole Breast cancer treatment break throughs https://www.onedaymd.com/2024/08/ivermectin-in-stage-4-cancers-2024.html

0 · Reply

taxplanr Jun. 26 at 7:14 PM

Ivermectin and Menbendazole Glioblastoma testimonial after 5 months $BNTX $CVAC $MRNA $BMY https://makismd.substack.com/p/ivermectin-and-mebendazole-testimonial-52f?utm_source=post-email-title&publication_id=1385328&post_id=166913331&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email

2 · Reply

Thestocktraderhubzee Jun. 26 at 3:32 PM

$CVAC UBS Downgrades CureVac to Neutral, Lowers Price Target to $5.5

0 · Reply

taxplanr Jun. 26 at 1:47 PM

$BNTX $MRNA $PFE $CVAC American Academy of Pediatrics throws the CDC vaccine guidelines under the bus Who will people listen to? https://karenkingston.substack.com/p/american-academy-of-pediatrics-discredits?utm_source=post-email-title&publication_id=1103773&post_id=166846433&utm_campaign=email-post-title&isFreemail=false&r=18m8lm&triedRedirect=true&utm_medium=email

1 · Reply

taxplanr Jun. 26 at 1:43 PM

CDC picked apart and exposed at first ACIP meeting with new members $BNTX $MRNA $PFE $CVAC https://childrenshealthdefense.org/defender/acip-advisers-cdc-covid-vaccine-safety-claims/?utm_source=luminate&utm_medium=email&utm_campaign=defender&utm_id=20250625

0 · Reply

CureVac Announces Voting Results of General Meeting

Jun 12, 2025, 12:05 PM EDT - 4 weeks ago

Top Stock Movers Now: Oracle, Boeing, CureVac, and More

BA ORCL

Jun 12, 2025, 11:07 AM EDT - 4 weeks ago

BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal

BNTX

Jun 12, 2025, 7:11 AM EDT - 4 weeks ago

BioNTech to Buy CureVac in $1.25 Billion Deal. Both Stocks Are Rising.

BNTX

Jun 12, 2025, 7:03 AM EDT - 4 weeks ago

BioNTech to acquire CureVac in $1.25 billion all-stock deal

BNTX

May 20, 2025, 7:15 AM EDT - 2 months ago

CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates

May 15, 2025, 4:45 PM EDT - 2 months ago

CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE

Apr 10, 2025, 12:59 PM EDT - 3 months ago

CureVac N.V. (CVAC) Q4 2024 Earnings Call Transcript

Apr 10, 2025, 7:30 AM EDT - 3 months ago

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update

Apr 8, 2025, 7:25 AM EDT - 3 months ago

CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025

Apr 7, 2025, 7:15 AM EDT - 3 months ago

CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer

Mar 28, 2025, 12:45 PM EDT - 3 months ago

CureVac Shares Rise on Patent Confirmation Amid BioNTech Lawsuit

BNTX

Mar 28, 2025, 8:58 AM EDT - 3 months ago

European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps

Mar 27, 2025, 6:22 PM EDT - 3 months ago

European Patent Office declares CureVac mRNA patent valid

Mar 27, 2025, 4:30 PM EDT - 3 months ago

CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE

Feb 18, 2025, 7:15 AM EST - 5 months ago

CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World's Top Innovators

Jan 8, 2025, 4:55 PM EST - 6 months ago

CureVac: Latest GBM Data Bodes Well For Next Program Check Point

Nov 12, 2024, 3:08 PM EST - 8 months ago

CureVac N.V. (CVAC) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 7:20 AM EST - 8 months ago

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

Nov 7, 2024, 7:30 AM EST - 8 months ago

CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024

Nov 4, 2024, 7:20 AM EST - 9 months ago

CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer

Nov 4, 2024, 7:15 AM EST - 9 months ago

CureVac to Present at the 12th International mRNA Health Conference

Oct 28, 2024, 8:10 AM EDT - 9 months ago

CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Oct 8, 2024, 5:50 AM EDT - 10 months ago

Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents

BNTX PFE

Sep 13, 2024, 8:15 AM EDT - 10 months ago

CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress

Sep 12, 2024, 7:15 AM EDT - 10 months ago

CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program

Sep 9, 2024, 7:15 AM EDT - 11 months ago

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress

Aug 15, 2024, 7:30 AM EDT - 11 months ago

CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update

Aug 15, 2024, 7:20 AM EDT - 11 months ago

CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma

Aug 15, 2024, 7:15 AM EDT - 11 months ago

CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board

Jul 11, 2024, 7:15 AM EDT - 1 year ago

CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech

Jul 11, 2024, 7:00 AM EDT - 1 year ago

Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer

Jul 3, 2024, 10:18 AM EDT - 1 year ago

GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines

GSK

Jul 3, 2024, 7:53 AM EDT - 1 year ago

CureVac's stock soars on GSK's $1.56 billion deal for its COVID-19 and flu vaccines

GSK

Jul 3, 2024, 2:40 AM EDT - 1 year ago

GSK and CureVac to Restructure Collaboration into New Licensing Agreement

GSK

Jul 3, 2024, 2:40 AM EDT - 1 year ago

CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities

Jul 3, 2024, 2:26 AM EDT - 1 year ago

GSK buys full rights to make COVID, influenza vaccines from CureVac

GSK

Apr 24, 2024, 3:12 PM EDT - 1 year ago

CureVac N.V. (CVAC) Q4 2023 Earnings Call Transcript

Apr 24, 2024, 7:30 AM EDT - 1 year ago

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update

Apr 24, 2024, 7:20 AM EDT - 1 year ago

CureVac Appoints Thaminda Ramanayake as New Chief Business Officer

Apr 24, 2024, 7:20 AM EDT - 1 year ago

CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK

Apr 18, 2024, 7:15 AM EDT - 1 year ago

CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024

Apr 16, 2024, 7:15 AM EDT - 1 year ago

CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines

Apr 4, 2024, 7:15 AM EDT - 1 year ago

CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK

Jan 5, 2024, 7:59 AM EST - 1 year ago

CureVac stock gains as COVID vaccine candidates show promise

Jan 5, 2024, 7:30 AM EST - 1 year ago

CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform

Dec 19, 2023, 9:35 AM EST - 1 year ago

CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE

Nov 14, 2023, 3:15 PM EST - 1 year ago

CureVac N.V. (CVAC) Q3 2023 Earnings Call Transcript

Nov 14, 2023, 7:30 AM EST - 1 year ago

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update

Jordand91 Jul. 11 at 6:55 PM

$NVAX go and check out $CVAC has a lot more promise than nova. Actually everything at this point has more promise than nova

2 · Reply

taxplanr Jul. 11 at 1:10 PM

$BNTX $MRNA $CVAC $BMY there is no future for malignantRNA in medicine

1 · Reply

taxplanr Jul. 9 at 2:20 PM

$BNTX $MRNA $CVAC $NVAX only sales plan https://jonfleetwood.substack.com/p/pegasus-uk-to-run-largest-ever-national

0 · Reply

StocktwitsNews Jul. 8 at 5:05 AM

1 · Reply

justiceforb_85 Jul. 3 at 8:05 PM

$CVAC when does the deal close?

0 · Reply

taxplanr Jun. 30 at 2:31 PM

$MRNA $BNTX $CVAC $BMY please let everyone know about the Ivermectin Menbendazole Breast cancer treatment break throughs https://www.onedaymd.com/2024/08/ivermectin-in-stage-4-cancers-2024.html

0 · Reply

taxplanr Jun. 26 at 7:14 PM

2 · Reply

Thestocktraderhubzee Jun. 26 at 3:32 PM

$CVAC UBS Downgrades CureVac to Neutral, Lowers Price Target to $5.5

0 · Reply

taxplanr Jun. 26 at 1:47 PM

1 · Reply

taxplanr Jun. 26 at 1:43 PM

0 · Reply

taxplanr Jun. 25 at 6:22 PM

$BNTX $MRNA $PFE $CVAC “Our findings suggest possible indirect transmission of ingredients or products of the COVID-19 vaccines, presumably through shedding, from people who received one or more of the COVID-19 injections." It just sounds like a bioweapon https://ijvtpr.com/index.php/IJVTPR/article/view/113

0 · Reply

taxplanr Jun. 25 at 4:05 PM

Did you know John Hoppkins University owns the patent for treating colon cancer with Menbendazole? $BNTX $MRNA $CVAC $BMY https://patents.google.com/patent/US11110079B2/en

0 · Reply

taxplanr Jun. 25 at 1:40 PM

$CVAC did 50% more volume than $BNTX did yesterday ... reminds me of that line about Will Rogers

0 · Reply

taxplanr Jun. 24 at 1:48 PM

The $BNTX $CVAC deal is another scam for $PFE to off load liability onto useful retail idiots

0 · Reply

Saif101 Jun. 24 at 1:41 PM

$CVAC lawsuit yes I can smell it !!

0 · Reply

ZacksResearch Jun. 20 at 5:03 PM

$CVAC surges 40.8% in a month — what's driving the rally? BioNTech's acquisition of CureVac for $1.25B in an all-stock deal, offering a 55% premium on CVAC's three-month volume-weighted average price, is the catalyst. The move boosts BNTX's mRNA cancer research capabilities and expands its oncology pipeline significantly. Discover the strategic impact here 👉 https://www.zacks.com/commentary/2520847/curevac-soars-41-in-a-month-on-a-125b-buyout-offer-from-biontech?cid=sm-stocktwits-2-2520847-body&ADID=SYND_STOCKTWITS_TWEET_2_2520847_BODY

0 · Reply

ZacksResearch Jun. 20 at 3:36 PM

$CVAC up 41% — but is this just the beginning? The $1.25 billion buyout offer from BioNTech aims to fast-track mRNA therapy development, a clear strategic play. Full deal details and what it could mean for investors 👉 https://www.zacks.com/stock/news/2520847/curevac-soars-41-in-a-month-on-a-125b-buyout-offer-from-biontech?cid=sm-stocktwits-2-2520847-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2520847_TEASER

0 · Reply

taxplanr Jun. 20 at 3:34 PM

Another amazing Breast cancer treatment success with Ivermectin Fenbendazole and Methylene Blue $BNTX $CVAC $BMY $MRNA https://makismd.substack.com/p/ivermectin-and-fenbendazole-and-methylene?utm_source=post-email-title&publication_id=1385328&post_id=166377262&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email

1 · Reply

taxplanr Jun. 19 at 2:49 AM

malignantRNA shareholders will want to share with friends $BNTX $MRNA $PFE $CVAC https://x.com/zaidkdahhaj/status/1935196559202992649?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1935196559202992649%7Ctwgr%5Ed70386752bdddf6eb6884ac802698487ccd3cdd8%7Ctwcon%5Es1_c10&ref_url=https%3A%2F%2Fwww.infowars.com%2Fposts%2Fwatch-mainstream-media-tells-truth-about-big-pharma-fluoride-toxic-american-diet-in-wacky-ai-generated-video

1 · Reply

taxplanr Jun. 18 at 5:46 PM

Ivermectin and Menbendazole cure Breast cancer $BNTX $CVAC $BMY $MRNA https://makismd.substack.com/p/ivermectin-and-mebendazole-testimonial-3f0?utm_campaign=email-half-post&r=18m8lm&utm_source=substack&utm_medium=email

1 · Reply

taxplanr Jun. 18 at 2:25 PM

$BNTX Died Suddenly 2 : Nanosapiens $MRNA $PFE $CVAC https://karenkingston.substack.com/p/ds2-nanosapiens-can-the-merger-of?utm_source=post-email-title&publication_id=1103773&post_id=166189314&utm_campaign=email-post-title&isFreemail=false&r=18m8lm&triedRedirect=true&utm_medium=email

1 · Reply

taxplanr Jun. 17 at 11:46 PM

Another CDC plandemic conspirator resigns $BNTX $CVAC $MRNA $PFE https://childrenshealthdefense.org/defender/cdc-scientist-who-drove-covid-rsv-vaccine-policies-resigns-in-protest/?utm_source=truth&utm_medium=social&utm_campaign=defender&utm_id=20250617

1 · Reply

Market Cap	1.22B
Revenue (ttm)	579.12M
Net Income (ttm)	175.50M
EPS (ttm)	N/A
PE Ratio	5.93
Forward PE	N/A
Profit Margin	30.30%
Debt to Equity Ratio	0.00

Volume	1,016,200
Avg Vol	1,358,044
Day's Range	N/A - N/A
Shares Out	224.34M
Stochastic %K	33%
Beta	2.53
Analysts	Hold
Price Target	$4.83